ѿapp
Edit Profile
Manage Subscriptions
CME Tracker
Log Out
Login
Sign Up
ѿapp
Back
Allergy & Immunology
Anesthesiology
Cardiology
Critical Care
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology
Genetics
Geriatrics
HIV / AIDS
Hospital-Based Medicine
Infectious Disease
Nephrology
Neurology
Nursing
OB / GYN
Oncology / Hematology
Ophthalmology
Orthopedics
Pain Management
Pathology
Pediatrics
Pharmacy
Primary Care
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Transplantation
Urology
Perspectives
Health Policy
Meetings
Special Reports
Break Room
Conditions
Back
Condition Centers
DocAudio
Making the Rounds
Medical Journeys
Society Partners
Back
AAD Reading Room
ACR Reading Room
AGA Reading Room
ASCO Reading Room
Endocrine Society Reading Room
IDSA Reading Room
Making the Rounds
>
AML
Treatment Updates for Relapsed/Refractory AML
In round one of their discussion on Acute Myeloid Leukemia, Catherine Lai, MD, and Alice Mims, MD, discuss treatment updates from EHA2024 for recurrent/progressive AML patients.
September 18, 2024 • 4 mins 32 secs
Up Next
Treatment Updates for Relapsed/Refractory AML
▶ 4 mins
2024 Update on Menin Inhibitors in AML
▶ 3 mins
I-Data study: Newly Diagnosed IDH Mutated AML Patients
▶ 3 mins
Comparing IDH1 Inhibitors: Ivosidenib vs. Olutasidenib in Relapsed/Refractory Settings
▶ 3 mins
Exploring IRAK4 and FLT3 Inhibitors in AML: The Take AIM Study
▶ 2 mins
